The global sepsis diagnostics market size is expected to reach USD 1.18 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.5% from 2021 to 2027. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period.

Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions for sepsis are expected to facilitate market growth over the forecast period. In May 2018, T2 Biosystems, Inc., a U.S.-based emerging diagnostic solutions company, received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens.

The outbreak of COVID-19 is another important factor boosting the demand for sepsis diagnostics around the globe. Symptoms of sepsis such as multiorgan injuries develop in around 2.0% to 5.0% of COVID-19 cases 8 to 10 days post-hospitalization, based on the estimates of the Global Sepsis Alliance. To manage this situation, the Biomedical Advanced Research and Development Authority, in May 2020, extended its partnership with Beckman Coulter for the development of a digital algorithm to detect sepsis in patients with COVID-19.

Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/sepsis-diagnostics-market

Sepsis Diagnostics Market Report Highlights

• By product, blood culture media held the largest share in 2020 as it is the most accurate mode of testing for the diagnosis of this disease. The software segment is anticipated to witness the fastest growth over the forecast period owing to new product developments in this field
• On the basis of technology, the molecular diagnostics segment is anticipated to exhibit a lucrative CAGR over the forecast period owing to its high sensitivity, accuracy, and less turnaround time
• Based on the pathogen, in 2020, the bacterial sepsis segment held the largest revenue share owing to its high prevalence
• North America dominated the market in 2020 due to high awareness, a favorable reimbursement scenario, and the presence of established players
• The Asia Pacific is projected to witness lucrative growth over the forecast period owing to the presence of a large target population in emerging economies, such as India and China

Key Companies & Market Share Insights

The key players operating in the market are adopting inorganic growth strategies, such as mergers and partnerships, for the development of novel diagnostic solutions. For instance, in January 2020, Roche and Inotrem SA, a France-based company, went into a strategic agreement for the commercialization of a companion diagnostics test intended for septic shock. Moreover, in May 2020, the Biomedical Advanced Research and Development Authority (BARDA) collaborated with Beckman Coulter for the development of a digital algorithm to identify sepsis in patients with COVID-19. Some prominent players in the global sepsis diagnostics market include bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Luminex Corporation, Bruker Corporation, Amara Health Analytics, Wolters Kluwer N.V., Cerner Corporation, Epic Systems Corporation, Mckesson Corporation, GE Healthcare, Koninklijke Philips N.V.

Browse Full Report (Tables & Figures) @https://www.grandviewresearch.com/industry-analysis/sepsis-diagnostics-market